Nuwiq dosing for girls and women with hemophilia A surgery
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial studies how to dose Nuwiq (a factor medicine) and track outcomes in girls and women with hemophilia A who need major surgery. It may help confirm the best way to manage bleeding risk around surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a girl or woman (at least 12 years old) with hemophilia A
- You are scheduled for major surgery that requires factor treatment, including planned or emergency surgery
- You can sign consent (or a parent/legal guardian can if you’re a minor)
- You do not have other bleeding/clotting disorders besides hemophilia A
- You do not have an inhibitor to FVIII (the body’s antibodies that can block the medicine)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
This early-phase study tests an FVIII gene therapy to help your body make more of the missing clotting factor in hemophilia A. It’s aimed at adults with severe low FVIII levels who have already used FVIII replacement products for a long time and have not developed an immune blocker (an inhibitor).
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.